P3 Health Partners Inc.

PIII

US7444131053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
0.4503 ^USD	-20.40%		-19.80%	-68.06%

05-24	P3 Health Partners Inc. announced that it has received $42.2598 million in funding from Chicago Pacific Founders, Alyeska Investment Group, L.P., Leavitt Equity Partners, Armistice Capital LLC and other investors	CI
05-22	P3 Health Partners Inc. announced that it expects to receive $42.2598 million in funding from Chicago Pacific Founders	CI

P3 Health Partners Inc. announced that it has received $42.2598 million in funding from Chicago Pacific Founders, Alyeska Investment Group, L.P., Leavitt Equity Partners, Armistice Capital LLC and other investors

May 23, 2024

On May 24, 2024, P3 Health Partners Inc. closed the transaction.

Latest news about P3 Health Partners Inc.

P3 Health Partners Inc. announced that it has received $42.2598 million in funding from Chicago Pacific Founders, Alyeska Investment Group, L.P., Leavitt Equity Partners, Armistice Capital LLC and other investors	05-23	CI
P3 Health Partners Inc. announced that it expects to receive $42.2598 million in funding from Chicago Pacific Founders	05-21	CI
P3 Health Partners Inc. Announces President Changes	05-09	CI
Earnings Flash (PIII) P3 HEALTH PARTNERS Reports Q1 Revenue $388.5M, vs. Street Est of $357.2M	05-08	MT
Transcript : P3 Health Partners Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
P3 Health Partners Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
P3 Health Partners Inc. Provides Earnings Guidance for the Year 2024	05-08	CI
P3 Health Partners Inc. Announces CEO Changes	05-08	CI
BTIG Research Downgrades P3 Health Partners to Neutral From Buy	04-01	MT
Transcript : P3 Health Partners Inc., Q4 2023 Earnings Call, Mar 28, 2024	03-28
P3 Health Partners Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Earnings Flash (PIII) P3 HEALTH PARTNERS Reports Q4 Revenue $346.9M, vs. Street Est of $302.7M	03-28	MT
P3 Health Partners Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-28	CI
P3 Health Partners Inc. Reaffirms Earnings Guidance for the full-year ending December 31, 2024	03-15	CI
Lake Street Adjusts Price Target on P3 Health Partners to $4.50 From $9, Maintains Buy Rating	03-14	MT
Transcript : P3 Health Partners Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	01-10
Global markets live: J Sainsbury, Intel, Tesla, Boeing, Amazon...	01-10
P3 Health Partners Reaffirms 2023 Revenue Guidance, Issues 2024 Outlook	01-10	MT
In wait-and-see mode	01-10
P3 Health Partners Inc. Reaffirms Earnings Guidance for the Year Ended December 31, 2023 and Provides Earnings Guidance for the Year Ending December 31, 2024	01-09	CI
Transcript : P3 Health Partners Inc., Q3 2023 Earnings Call, Nov 08, 2023	11-08
Earnings Flash (PIII) P3 HEALTH PARTNERS Posts Q3 Revenue $288.4M, vs. Street Est of $293.3M	11-08	MT
P3 Health Partners Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
P3 Health Partners Inc. Provides Earnings Guidance for the Year 2023	11-08	CI
BTIG Initiates P3 Health Partners With Buy Rating, Price Target is $5	23-09-01	MT

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patientâs care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from more than 250 disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 2,800 affiliated primary care providers across the country. Its local teams of health care professionals manage the care of thousands of patients in 23 counties across five states.

Sector

Biotechnology & Medical Research

Calendar

2024-10-16 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for P3 Health Partners Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4503 USD

Average target price

2.7 USD

Spread / Average Target

+499.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
P3 HEALTH PARTNERS INC.	-68.06%	72.6M
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
CELLTRION, INC.	-13.50%	26.03B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	10.64B

Other Biotechnology & Medical Research